Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer

被引：0
作者：
Kentaro Sudo
Takeshi Ishihara
Nobuto Hirata
Fumiaki Ozawa
Tadashi Ohshima
Ryosaku Azemoto
Kenji Shimura
Takeshi Nihei
Takayoshi Nishino
Akihiko Nakagawa
Kazuyoshi Nakamura
Taro Hara
Motohisa Tada
Rintaro Mikata
Katsunobu Tawada
Osamu Yokosuka
So Nakaji
Taketo Yamaguchi
机构：
[1] Chiba Cancer Center,Department of Gastroenterology
[2] Chiba University,Department of Gastroenterology and Nephrology, Graduate School of Medicine
[3] Kameda Medical Center,Department of Gastroenterology
[4] Saitama Medical University,Department of Hepato
[5] Saitama Red Cross Hospital,biliary
[6] Kimitsu Chuo Hospital,pancreatic Surgery, Saitama Medical Center
[7] Asahi General Hospital,Department of Gastroenterology
[8] Mito Saiseikai General Hospital,Department of Gastroenterology
[9] Tokyo Women’s Medical University Yachiyo Medical Center,Department of Gastroenterology
[10] Numazu City Hospital,Department of Internal Medicine
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 73卷
关键词：
Pancreatic cancer; S-1; Gemcitabine; Randomized controlled study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：389 / 396
页数：7
相关论文
共 50 条
  • [21] Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04)
    Sugiura, Teiichi
    Toyama, Hirochika
    Fukutomi, Akira
    Asakura, Hirofumi
    Takeda, Yuriko
    Yamamoto, Kouji
    Hirano, Satoshi
    Satoi, Sohei
    Matsumoto, Ippei
    Takahashi, Shinichiro
    Morinaga, Soichiro
    Yoshida, Makoto
    Sakuma, Yasunaru
    Iwamoto, Hidetaka
    Shimizu, Yasuhiro
    Uesaka, Katsuhiko
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2023, 30 (11) : 1249 - 1260
  • [22] A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
    Oettle, H
    Richards, D
    Ramanathan, RK
    van Laethem, JL
    Peeters, M
    Fuchs, M
    Zimmermann, A
    John, W
    Von Hoff, D
    Arning, M
    Kindler, HL
    ANNALS OF ONCOLOGY, 2005, 16 (10) : 1639 - 1645
  • [23] S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma
    Stine Braendegaard Winther
    Jon Kroll Bjerregaard
    Katrine Rahbek Schonnemann
    Mathilde Weisz Ejlsmark
    Merete Krogh
    Helle Anita Jensen
    Per Pfeiffer
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 573 - 578
  • [24] A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer
    Chao, Yee
    Wu, Chen-Yi
    Wang, Jack P.
    Lee, Rheun-Chuan
    Lee, Wei-Ping
    Li, Chung-Pin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (03) : 637 - 642
  • [25] S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma
    Winther, Stine Braendegaard
    Bjerregaard, Jon Kroll
    Schonnemann, Katrine Rahbek
    Ejlsmark, Mathilde Weisz
    Krogh, Merete
    Jensen, Helle Anita
    Pfeiffer, Per
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (03) : 573 - 578
  • [26] Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.
    Imaoka, Hiroshi
    Kou, Tadayuki
    Tanaka, Masao
    Egawa, Shinichi
    Mizuno, Nobumasa
    Hijioka, Susumu
    Hara, Kazuo
    Yazumi, Shujiro
    Shimizu, Yasuhiro
    Yamao, Kenji
    EUROPEAN JOURNAL OF CANCER, 2016, 54 : 96 - 103
  • [27] Meta-analysis of gemcitabine and cisplatin combination chemotherapy versus gemcitabine alone for pancreatic cancer
    Huang, Diyu
    Fang, Jie
    Luo, Gaojian
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (05) : 104 - 108
  • [28] Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer
    Bunzo Nakata
    Ryosuke Amano
    Shigetomi Nakao
    Tatsuro Tamura
    Osamu Shinto
    Toshiki Hirakawa
    Yoshihiro Okita
    Nobuya Yamada
    Kosei Hirakawa
    Journal of Experimental & Clinical Cancer Research, 29
  • [29] Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma
    Suzuki, Takashi
    Mori, Shozo
    Shimizu, Takayuki
    Tago, Kazuma
    Harada, Nobuhiro
    Park, Kyung-Hwa
    Sakuraoka, Yuhki
    Shiraki, Takayuki
    Iso, Yukihiro
    Aoki, Taku
    Kubota, Keiichi
    IN VIVO, 2019, 33 (06): : 2027 - 2035
  • [30] Biweekly gemcitabine plus S-1 for locally advanced and metastatic pancreatic cancer: a preliminary feasibility study
    Wada, Keita
    Sano, Keiji
    Amano, Hodaka
    Miura, Fumihiko
    Toyota, Naoyuki
    Ito, Hiromichi
    Shibuya, Makoto
    Ikeda, Yutaka
    Kainuma, Masahiko
    Takada, Tadahiro
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2015, 22 (09) : 692 - 698
12345